Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 476-490-9 | CAS number: 286938-65-6
Endpoint summary
Administrative data
Description of key information
Myristyl Trisiloxane shows no acute toxicity effects
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP complaint with international guidelines
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP compliant with international guidelines
Additional information
The limit test via both oral and dermal route shows no evidence of toxicity until 2000 mg/kg bw.
The in vivo tests were all performed in 2007.
Justification for selection of acute toxicity – oral endpoint
Well performed and exhaustive study
Justification for selection of acute toxicity – dermal endpoint
Well performed and exhaustive study
Justification for classification or non-classification
Myristyl Trisiloxane doesen't show any evidence of toxicity in all limit tests. The limit tests via oral and dermal doesen't show any evince of toxicity until 2000 mg/kg bw; therefore, based on REGULATION (EC) No 1272/2008 no classification is required.
Even though there is no studies for the assessment of respiratory toxicity, it can be assumed that absorption via airways cannot be higher compared to both oral and dermal administration. Therefore, as there is no evidence of toxicity by both oral and dermal route, it can be concluded that also the respiratory tract is not raising furtyer concern.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
